Bhat smells conspiracy behind Shiroor seer’s decision to contest polls from Udupi

Bengaluru, May 24: In an effort to protect passengers and staff from the risk of COVID-19 transmission, the Bangalore International Airport Limited (BIAL) has introduced a parking-to-boarding contactless journey at the airport.

With a greater emphasis on minimum touch and minimum exposure between passengers and airport personnel, BIAL aims to minimise all physical contact at the airport. The technology will continue to enable a seamless airport journey, with greater emphasis on health and safety.

"As the gateway to a new India, BLR Airport has a key role to play in helping passengers through this global health crisis by reassuring them that their safety is our top priority. We have introduced innovative contactless procedures to minimise exposure at the airport," said Hari Marar, MD and CEO, BIAL.

"These enhancements demonstrate our continued commitment to keep our passengers safe in this environment. We believe our new measures will boost confidence among passengers," continued Marar.

"BLR Airport is all geared up to welcome our passengers back and - working with various government departments - we're committed to offering them a safe experience by implementing the best-in-class standards, procedures and practices," Marar added.

Earlier, Civil Aviation Minister Hardeep Singh Puri said that domestic flight operations will resume from May 25 noting that all airlines and airports were ready but it is not viable to keep the middle seat vacant as it will lead to hike in the ticket price and prescribed social distancing norms would still not be met. 

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

New Delhi, Mar 19: The Supreme Court on Thursday upheld the validity of Karnataka's 2018 reservation law, which granted reservation in promotion to employees belonging to SC and ST categories.

A bench headed by Justice DY Chandrachud holds that applications filed by a group of general category employees for applying 'post-based quota' and the principle of the creamy layer at entry-level in public employment are not maintainable.

The apex court had, in November last year, reserved its order on the applications filed by general category candidates in the matter.

In May last year, the top court had upheld the law allowing reservations in promotions for SC and ST candidates with consequential seniority.